Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria: - Patient has a histologically proven prostatic adenocarcinoma.~* Patient has been on a gonadotropin releasing hormone (GnRH) agonist treatment for a duration of at least 1 year.~* Karnofsky index greater than or equal to (\>=) 70 %.~* Patient who, after having been clearly informed, has given his written consent to participate in the study.~Exclusion Criteria:~* Patient included in a therapeutic trial in the 3 months preceding the inclusion visit.~* Prescription of agonist planned in the context of neo-adjuvant hormonotherapy.~* Patient has symptomatic bone metastases.~* Patient already treated with hormonotherapy for his prostate cancer or has received a hormonal treatment other than a GnRH agonist for this cancer (apart from palliative care of flare-up with anti-androgens).~* Patient is unable to understand the information regarding the study provided to him, of giving his consent or who has refused to sign the informed consent sheet.~* Patient for whom risk follow up could not be guaranteed within the conditions stipulated in the protocol or is unable to complete the self-evaluation questionnaires.~* Diabetic, or patient with severe progressive disease: kidney, liver, cardiovascular (especially high uncontrolled BP), psychiatric.~* Has a Thromboembolic history or concomitant thromboembolic disease.~* Patient had hepatocellular insufficiency or hepatic cytolysis (serum glutamic oxaloacetic transaminase / serum glutamic pyruvate transaminase \[SGOT/SGPT\] \>3 times laboratory normal range).~* Patient had a contra-indication to one of the study drugs.~* Patient receiving corticotherapy or concomitant prescription for non-selective monoamine oxidase inhibitors (MAOI), serotonin re-uptake inhibitors, clonidine, gabapentine, veripride, tibolone or beta-alanine.~* Patient was undergoing medical treatment for a depressive phase or had been treated for this during the previous 2 years before inclusion.~* Patient with a history of congenital galactosemy, poor absorption of glucose or galactose syndrome or even a lactase deficiency.~* Patient had another cancer in the 5 previous years excluding basocellular epithelioma or in situ carcinoma.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cyproterone acetate (Type: EXPERIMENTAL): Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, cyproterone acetate 50 mg, tablet-in-capsule, along with cyproterone acetate placebo-matching capsule, orally, once daily in the morning and cyproterone acetate 50 mg, tablet-in-capsule, orally, once daily in the evening for 8 weeks. Cyproterone acetate placebo-matching capsule, orally, once daily in the morning for the next 2 weeks.
- Medroxyprogesterone acetate (Type: EXPERIMENTAL): Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, medroxyprogesterone acetate 10 mg, tablet-in-capsule, along with medroxyprogesterone acetate placebo-matching capsule, orally, once daily in the morning and medroxyprogesterone acetate 10 mg, tablet-in-capsule, orally, once daily in the evening for 8 weeks. Medroxyprogesterone acetate placebo-matching capsule, orally, once daily in the morning for the next 2 weeks.
- Venlafaxine (Type: EXPERIMENTAL): Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, venlafaxine 75 mg, capsule, orally, once daily in the morning and venlafaxine placebo-matching capsule, orally, once daily in the evening for 8 weeks. Venlafaxine 37.5 mg, capsule, orally, once daily in the evening for the next 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete